Selank: Research & Studies
Scientific evidence, clinical trials, and research findings
📌TL;DR
- •4 clinical studies cited
- •Overall evidence level: low
- •See research gaps below
Research Studies
A New Generation of Drugs - Synthetic Peptides Based on Natural Regulatory Peptides
Kolomin TA, Shadrina MI, Slominsky PA, Limborska SA, Myasoedov NF (2013) • Neuroscience and Medicine
Comprehensive review of Selank and Semax covering preclinical and limited clinical data on anxiolytic, neuroprotective, immunomodulatory, and transcriptomic effects
Key Findings
- Selank reported as anxiolytic comparable to medazepam without sedation
- Approximately 40% of GAD patients showed rapid response by day 3
- Broad transcriptomic modulation of neurotransmission and immune genes
Physiological Effects of Selank and Its Fragments
Koroleva SV, Mjasoedov NF (2019) • Biology Bulletin
Narrative review of Selank pharmacology covering anxiolytic effects, enkephalinase inhibition, immunomodulation, and fragment activity
Key Findings
- Selank inhibits enkephalin-degrading enzymes, increasing endogenous enkephalin levels
- Anxiolytic efficacy comparable to medazepam in GAD/neurasthenia
- Immunomodulatory and antiviral effects via IFN and cytokine modulation
Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo
Inozemtseva LS, Karpenko EA, Dolotov OV, et al. (2008) • Doklady Biological Sciences
Intranasal Selank at 250 and 500 mcg/kg increased hippocampal BDNF mRNA at 3 hours and BDNF protein at 24 hours in rats
Key Findings
- Selank upregulated BDNF mRNA in hippocampus within 3 hours
- BDNF protein levels increased by 24 hours at both doses tested
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
Volkova A, Shadrina MI, Kolomin TA, et al. (2016) • Frontiers in Pharmacology
Selank altered expression of 45 neurotransmission genes in rat frontal cortex at 1 hour, with changes overlapping GABA-induced transcriptional signatures
Key Findings
- Selank modulated 45 genes at 1 hour and 22 genes at 3 hours after administration
- Gene expression changes positively correlated with exogenous GABA effects
- Supports allosteric modulation of GABAergic system as a mechanism
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles · 30+ comparisons · 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 120+ community reports
View community protocolsExplore research gaps across all peptides → | View clinical trial pipeline →
Research Overview#
The research literature on Selank spans hundreds of preclinical studies across multiple therapeutic areas. Below is a structured review of the key studies, systematic reviews, and identified research gaps.
Musculoskeletal Research#
What do they conclude about safety?
-
Reported safety/tolerability across reviews is generally favorable but weakly characterized: • Reviews emphasize that Selank is a short peptide with rapid degradation to amino acids, suggesting low intrinsic toxicity. Narrative accounts state an absence of typical sedative/muscle-relaxant side effects seen with benzodiazepines. However, explicit adverse-event data and systematic safety assessments are sparse. • Pharmacokinetics described include very short plasma half-life with rapid brain/plasma appearance after intranasal dosing; safety conclusions are mostly inferential/mechanistic rather than based on robust clinical AE reporting.
-
Comprehensive review articles exist, but they are narrative rather than systematic meta-analyses. They suggest potential anxiolytic efficacy for Selank in generalized anxiety disorder and neurasthenia, with heterogeneous findings and minimal/absent benefit in panic disorder. Safety is portrayed as favorable with low toxicity and few typical anxiolytic side effects, but clinical adverse-event reporting is limited and formal systematic safety evaluations are lacking. No Selank-specific meta-analyses or high-quality systematic reviews of clinical outcomes were found.
Supporting artifact
| Reference (year, journal) | Review type | Scope (focus, populations) | Efficacy conclusions | Safety conclusions | Notes/limitations |
|---|---|---|---|---|---|
| Koroleva & Mjasoedov (2019), Biology Bulletin | Narrative / comparative review | Preclinical (in vitro, animal) and limited clinical data; anxiety-spectrum disorders (GAD, neurasthenia), immunomodulation, antiviral assays | Reports anxiolytic effects comparable to medazepam in some GAD/neurasthenia studies; preclinical cognitive, immunomodulatory and antiviral signals | Notes short blood half-life; authors state low toxicity and absence of typical anxiolytic side effects, but little systematic AE reporting | Descriptive synthesis without pooled estimates; heterogeneous clinical data and limited AE documentation |
| Kolomin et al. (2013), Neuroscience & Medicine | Comprehensive narrative review | Broad review of synthetic regulatory peptides with emphasis on Semax and Selank; extensive preclinical studies and some clinical observations | Summarizes preclinical anxiolytic, cognitive, neuroprotective, immunomodulatory and antiviral findings; clinical reports of rapid symptom reduction... | Mechanistic safety discussion (peptide metabolism to amino acids, low predicted toxicity); sparse formal clinical safety/adverse-event data | Largely preclinical evidence; clinical findings are limited, small, and not meta-analysed |
| Khavinson et al. (2021), Molecules | Systematic review (broad, mechanism-focused) | Global review of short peptides and regulation of gene expression; not Selank-specific, covers mechanistic potential across peptides | Describes mechanistic rationale that short peptides (including tuftsin-derivatives) can modulate gene expression and biological systems; does not p... | Discusses general favorable properties of short peptides (biodegradability, low toxic metabolites) but no Selank-specific safety synthesis | Indirect/evidence-of-mechanism review; not focused on clinical outcomes or pooled Selank data |
Systematic Reviews#
Summary of evidence
- We identified comprehensive narrative reviews specifically addressing Selank and its fragments, and one broad systematic review of short regulatory peptides that is not Selank-focused.
What reviews exist?
- Narrative/comprehensive reviews on Selank: • Koroleva & Mjasoedov (2019, Biology Bulletin): a comparative, narrative review synthesizing preclinical and limited clinical data on Selank’s physiological effects and fragments. • Kolomin et al. (2013, Neuroscience & Medicine): a comprehensive narrative review covering synthetic regulatory peptides (Semax and Selank) with extensive preclinical findings and limited clinical observations.
- Systematic reviews/meta-analyses: • No Selank-focused systematic reviews or meta-analyses were found. A broad systematic review on peptide regulation of gene expression mentions short peptides, providing mechanistic context but not clinical synthesis for Selank (Khavinson et al., 2021, Molecules).
What do they conclude about efficacy?
- Anxiety-spectrum disorders (primary clinical focus): • Koroleva & Mjasoedov summarize that Selank reduces behavioral manifestations of anxiety; in some clinical comparisons, its anxiolytic effect was described as comparable to medazepam in generalized anxiety disorder and neurasthenia. Effects were heterogeneous and reportedly weaker/absent in panic disorder. These conclusions are narrative, based on small and methodologically limited studies without pooled estimates. • Kolomin et al. report clinical observations of rapid reductions in anxiety, tension, and autonomic symptoms in patients with generalized anxiety, neurasthenia, or mixed anxiety states, alongside biomarker changes (e.g., modulation of enkephalins). Evidence remains primarily preclinical with limited, uncontrolled or small clinical studies; no meta-analytic effect sizes are provided.
- Other domains (preclinical/translational): • Both reviews describe immunomodulatory and antiviral activity, modulation of GABAergic/opioid systems, and neurotrophic gene-expression effects in animals and ex vivo systems. These suggest plausible mechanisms but do not establish clinical efficacy beyond anxiety-related indications.
Research Methodology#
Objective. We assessed the Selank literature to identify major research gaps and methodological limitations, and to propose studies most needed to advance the field.
Summary of limitations and gaps. Across accessible sources, Selank’s evidence base is dominated by preclinical findings and secondary reports, with a lack of accessible, well-described randomized, double-blind, placebo-controlled clinical trials. A 2024 review for clinicians notes Selank is a tuftsin-analogue heptapeptide marketed as a supplement and describes GABA-mimetic effects mainly from animal studies; it also highlights uninvestigated mechanistic targets (e.g., α2-δ VGCC subunits) and sparse formal safety surveillance, with no known withdrawal/death reports in the cited sources and few public-health inquiries—underscoring limited pharmacovigilance data (bonnet2024phenibut—anillegalfood pages 5-6). System-level analyses of Russia-developed peptides emphasize a lag in the adoption of GLP/GCP and other “good industry practices,” contributing to limited international recognition and potentially constraining trial rigor, reporting standards, and regulatory acceptability. Mechanistic/target engagement in humans is uncharacterized; available mechanistic claims (GABA-A allosteric modulation and gene-expression changes) come from animal data or in vitro work rather than human biomarker studies (bonnet2024phenibut—anillegalfood pages 5-6). Preclinical work in closely related heptapeptides (e.g., Semax) shows timing-dependent, short-lived behavioral effects and transcriptomic modulation under acute stress in rodents, which raises uncertainties about clinical dosing schedules and durability of effect for this class and illustrates the translational gap from preclinical endpoints to patient-relevant outcomes. Human pharmacokinetics/pharmacodynamics for intranasal Selank were not identified in the retrieved texts, and broader reviews stress that BBB penetration and PK remain general challenges for peptide drugs, reinforcing the need for rigorous PK/PD characterization. Collectively, these limitations point to deficiencies in trial design transparency, sample-size justification and power, standardized endpoints, human PK/PD and target engagement, long-term safety monitoring, and international regulatory alignment.
Most-needed studies. To address these gaps, several study types are highest priority: (1) a Phase I intranasal dose-escalation study in healthy volunteers to define human PK/PD, nasal absorption, safety/tolerability, and exploratory CNS biomarkers; (2) a multicenter, randomized, double-blind, placebo-controlled Phase II trial in generalized anxiety disorder or social anxiety disorder with pre-registered protocols, adequate power, and standardized endpoints (e.g., HAM-A, LSAS), followed by (3) an adaptive Phase IIb dose-finding trial to optimize regimen and frequency given potentially short-lived effects in this peptide class; (4) a crossover human target-engagement study using EEG/MEG and MRS (GABA) with timed sampling to confirm CNS effects and mechanism; (5) drug–drug interaction studies with SSRIs and benzodiazepines to assess safety and pharmacokinetics in real-world polypharmacy contexts; (6) a prospective long-term safety registry/pharmacovigilance program to capture rare and delayed adverse events; (7) a pragmatic comparative-effectiveness trial versus standard treatments (SSRI or benzodiazepine) assessing longer-term outcomes and functioning; and (8) a randomized adjunctive trial in alcohol/opioid withdrawal to translate preclinical attenuation signals into patient care.
Key artifact. The following artifact concisely maps limitations to concrete studies to close them:
| Domain | Specific limitation/gap | Evidence / examples from retrieved sources | Implication |
|---|---|---|---|
| Trial rigor | Lack of accessible randomized, double-blind, placebo-controlled RCT reports; blinding/controls unclear | No accessible detailed RCT data; literature/secondary mentions only; system-level practice gaps in trial standards | Efficacy claims lack confirmatory high-quality clinical evidence; risk of bias unknown |
| Sample sizes | Sample sizes for human studies not reported or unavailable | Absence of published, adequately powered trials or sample-size reporting in retrieved sources | Unclear statistical power; effect-size estimates unreliable |
| Endpoints | Outcomes mostly preclinical behavioral assays; no standardized clinical endpoints (e.g., HAM-A, LSAS) | Animal behavioral and transcriptomic endpoints dominate (Semax rodent studies) | Hard to translate preclinical signals to patient-relevant clinical benefit |
| Publication / language bias | Predominantly regional/Russian publications and limited international recognition | Stated lack of international recognition and lag in adoption of international practices | Potential publication/language bias; barriers to independent replication and peer scrutiny |
| Human PK/PD | Human pharmacokinetics and pharmacodynamics largely unreported/absent | No human PK/PD data in retrieved excerpts; reliance on animal data | Dose selection, exposure–response, and route (intranasal) optimization uncertain |
| Target engagement / mechanism | Human target-engagement data lacking; specific targets (e.g., VGCC α2-δ) not investigated | Explicit note that effect on VGCC α2-δ subunits has not been investigated; mechanism claims mainly preclinical GABAergic modulation (bonnet2024phen... | Mechanistic basis in humans unconfirmed; biomarker-driven development hampered |
| Safety surveillance | Sparse pharmacovigilance; few reported adverse-event series; no withdrawal/death cases noted in sources | "No known cases of withdrawal symptoms or death" and limited inquiries/reporting (bonnet2024phenibut—anillegalfood pages 5-6) | Long-term and rare safety risks may be undercharacterized |
| Duration of effect | Preclinical data for related peptide Semax show rapid but short-lived effects (minutes–hours) | Semax behavioral effects rapid and short-lived; timing-dependent outcomes in rodents | Unclear clinical dosing frequency and sustained-effect potential for Selank-class peptides |
| Regulatory / GLP–GCP alignment | Reported lag in implementation of modern good laboratory/clinical practices in domestic development | Authors note significant lag in 'good industry practices' and call for harmonization | Regulatory hurdles and limited international trial acceptability; reproducibility concerns |
| Study type / design | Population / indication | Key features (endpoints, controls) | Rationale (what gap it addresses) |
|---|---|---|---|
| Multi-center Phase II RCT (randomized, double-blind, placebo-controlled) | Adults with GAD or social anxiety disorder | Large sample (e.g., N≥200), pre-specified primary outcome (HAM-A or LSAS), standardized secondary outcomes, prospective safety monitoring, pre-regi... | Tests efficacy with rigorous trial design and adequate power to address trial-rigor and sample-size gaps |
| Phase I PK/PD and safety intranasal dose-escalation | Healthy volunteers (and a small patient cohort) | Single/Multi ascending dose, measure plasma (and where feasible CSF) concentrations, intranasal absorption, AE collection, exploratory PD biomarkers | Establishes human PK/PD, tolerability, and guides dose selection (addresses human PK/PD gap) |
| Phase IIb dose-finding (adaptive) | Patients with anxiety disorders | Multiple dose arms, adaptive allocation, patient-reported outcomes + clinician-rated scales, interim futility/superiority checks | Determines optimal therapeutic dose and dosing interval given uncertain duration of effect |
| Crossover human target-engagement study (biomarkers) | Healthy volunteers or patients | Within-subject crossover; EEG/MEG, MRS (GABA), pharmacodynamic assays, timed sampling post-dose | Demonstrates CNS target engagement and mechanism in humans (addresses VGCC/GABA target gaps) |
| Drug–drug interaction (DDI) study | Volunteers/patients on SSRIs or benzodiazepines | Assess PK interactions, safety endpoints, vital signs; evaluate additive/synergistic CNS effects | Clarifies combination safety and interaction potential for real-world polypharmacy scenarios (bonnet2024phenibut—anillegalfood pages 5-6) |
| Long-term safety registry / pharmacovigilance | All treated patients / supplement users | Prospective registry, AE reporting, pregnancy outcomes, serious AE capture, linkage to prescribing data | Addresses sparse safety surveillance and rare/long-term risks (bonnet2024phenibut—anillegalfood pages 5-6) |
| Comparative effectiveness pragmatic trial | Adults with GAD — Selank vs SSRI or benzodiazepine | Non-inferiority or superiority design, functional outcomes, longer follow-up (6–12 months) | Places Selank in clinical context vs standard treatments (addresses comparative-effectiveness gap) |
| RCT in special populations (substance withdrawal adjunct) | Patients undergoing alcohol/opiate withdrawal | Adjunctive randomized, blinded design vs placebo; standardized withdrawal scales; safety monitoring | Tests preclinical signals that Selank may attenuate withdrawal symptoms (translational gap) |
Top gaps and priority studies at a glance:
- Lack of accessible high-quality randomized, double-blind, placebo-controlled RCTs
- Absent human PK/PD data for intranasal Selank
- Unclear human target engagement; key targets (e.g., VGCC α2-δ) remain uninvestigated (bonnet2024phenibut—anillegalfood pages 5-6)
- Limited safety surveillance and sparse pharmacovigilance data despite supplement availability (bonnet2024phenibut—anillegalfood pages 5-6)
- Publication/language bias and limited alignment with international GLP/GCP standards
- Reliance on preclinical behavioral and transcriptomic endpoints with weak clinical translation
- Uncertain duration of effect and optimal dosing/frequency for Selank-class peptides
- Phase I intranasal PK/PD and safety dose-escalation study in healthy volunteers
- Multicenter Phase II randomized, double-blind, placebo-controlled efficacy trial in GAD or social anxiety disorder (bonnet2024phenibut—anillegalfood pages 5-6)
- Adaptive Phase IIb dose-finding trial to determine optimal regimen and dosing interval
- Human target-engagement crossover study using EEG/MRS (GABA) and timed biomarker sampling (bonnet2024phenibut—anillegalfood pages 5-6)
- Drug–drug interaction study with SSRIs and benzodiazepines to assess safety and PK interactions (bonnet2024phenibut—anillegalfood pages 5-6)
- Long-term safety registry and active pharmacovigilance program for treated patients and supplement users (bonnet2024phenibut—anillegalfood pages 5-6)
- Pragmatic comparative-effectiveness trial versus standard treatments (SSRIs/benzodiazepines) for real-world outcomes
- Randomized adjunctive trial testing Selank for attenuation of alcohol/opioid withdrawal symptoms
Blockquote: A concise bullet list (gaps then highest-priority studies) summarizing methodological limitations in the Selank literature and the studies needed to address them, with source citations for each item.
Conclusion. The current Selank literature lacks accessible, rigorous clinical trials, human PK/PD, and human target-engagement evidence; safety surveillance is sparse; and systemic GLP/GCP misalignment limits international acceptance. Priority investments include foundational human PK/PD and target-engagement studies, adequately powered multicenter RCTs with standardized endpoints, dose-optimization, comparative-effectiveness evaluations, and robust pharmacovigilance to define Selank’s true clinical value and risk profile.
Evidence Quality Assessment#
The evidence base for Selank currently consists primarily of preclinical studies. On the evidence hierarchy:
- Systematic reviews/meta-analyses: Limited availability
- Randomized controlled trials (human): Not completed
- Animal studies: Extensive body of research
- In vitro studies: Multiple cell culture experiments
- Case reports: Limited anecdotal evidence
Related Reading#
Where to Find Selank
Research-grade suppliers verified by our scoring methodology.
Frequently Asked Questions About Selank
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.